Ichiro Abe (2020) “Efficacy and Safety of Low-Dose Ipragliflozin, a Selective Sodium Glucose Transporter 2 Inhibitor, in Patients with Type 2 Diabetes Mellitus”, International Journal of Allied Medical Sciences and Clinical Research, 4(3), pp. 376–382. doi: 10.61096/ijamscr.v4.iss3.2016.376-382.